Amifampridine SERB



This medicine is authorised for use in the European Union.


Amifampridine Serb is a medicine used to treat the symptoms of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a disease in which patients have muscle weakness because of a failure of the nerves to transmit electrical impulses to the muscles.

Amifampridine Serb contains the active substance amifampridine and is a ‘generic medicine’. This means that Amifampridine Serb contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Firdapse. For more information on generic medicines, see the question-and-answer document here.

This EPAR was last updated on 24/05/2022

Authorisation details

Product details
Amifampridine SERB
Agency product number
Active substance
amifampridine phosphate
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
  • Lambert-Eaton Myasthenic Syndrome
  • Paraneoplastic Syndromes, Nervous System
  • Nervous System Neoplasms
  • Paraneoplastic Syndromes
  • Nervous System Diseases
  • Autoimmune Diseases of the Nervous System
  • Neurodegenerative Diseases
  • Neuromuscular Diseases
  • Neuromuscular Junction Diseases
  • Immune System Diseases
  • Autoimmune Diseases
  • Autoimmune Diseases of the Nervous System
  • Cancer
  • Neoplasms
Anatomical therapeutic chemical (ATC) code

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Avenue Louise 480
1050 Brussels

Product information

Amifampridine SERB - EMEA/H/C/005839 -

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Other nervous system drugs

Therapeutic indication

Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.

Assessment history

How useful was this page?

Add your rating